Why the study?
Heart failure recurrence after acute myocardial infarction remains high due to limited cardiac tissue repair, prompting the need to understand growth factor cardioprotective and regenerative actions and workable clinical delivery strategies.
Growth factor-based therapy and optimized delivery strategies represent a potential avenue for cardiac repair and regeneration after acute myocardial infarction.
Merits no change in post-MI care; leaves open rigorous trials of optimized growth factor delivery for regeneration.
Acute myocardial infarction (AMI) is one of the leading causes of death worldwide. Despite recent advances in clinical management, reoccurence of heart failure after AMI remains high, in part because of the limited capacity of cardiac tissue to repair after AMI-induced cell death. Growth factor-based therapy has emerged as an alternative AMI treatment strategy. Understanding the underlying mechanisms of growth factor cardioprotective and regenerative actions is important. This review focuses on the function of different growth factors at each stage of the cardiac repair process. Recent evidence for growth factor therapy in preclinical and clinical trials is included. Finally, different delivery strategies are reviewed with a view to providing workable strategies for clinical translation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: